Table 1. Previous therapy strategy baseline of patients from ALTER0303 trial.

Subgroup	Placebo (n=143)	Anlotinib (n=294)	Comparison between groups
Surgery
No	91 (63.64)	153 (52.04)	Fisher’s exact test P=0.0241
Yes	52 (36.36)	141 (47.96)
Chemotherapy
Second line	78 (54.55)	167 (56.80)	Fisher’s exact test P=0.3884
More than second line	65 (45.45)	123 (41.84)
Others (first line)	0 (0.00)	4 (1.36)
Chemotherapy regimens
Pemetrexed/platinum	94 (65.73)	209 (71.09)	Fisher’s exact test P=0.2700
Docetaxel/platinum	100 (69.93)	188 (63.95)	Fisher’s exact test P=0.2376
Paclitaxel/platinum	54 (37.76)	95 (32.31)	Fisher’s exact test P=0.2827
Vinorelbine/platinum	36 (25.17)	74 (25.17)	Fisher’s exact test P=1.0000
Gemcitabine/platinum	77 (53.85)	156 (53.06)	Fisher’s exact test P=0.9188
Radiotherapy
No	78 (54.55)	176 (59.86)	Fisher’s exact test P=0.3028
Yes	65 (45.45)	118 (40.14)
Target therapy
No	74 (51.75)	136 (46.26)	Fisher’s exact test P=0.3080
Yes	69 (48.25)	158 (53.74)